Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Surovatamig versus standard of care for previously untreated limited-stage nodal follicular lymphoma
ACTRN12626000311358Phase 3Not yet recruiting
- Sponsor
- Australasian Leukaemia & Lymphoma Group
- Start
- Apr 2027
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 6
01
Overview
Phase 3, randomised, open-label trial in follicular lymphoma (FL) comparing Surovatamig with Standard of care (2 arms). Primary endpoint: Event-free survival. Planned start Apr 2027; status: not yet recruiting.
02
Drugs
surovatamig
03
Conditions
follicular lymphoma (FL)
Beyond the preview
Go deeper on ACTRN12626000311358.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12626000311358.